血液疾病治疗与诊断：全球市场

全球血液疾病治疗和诊断市场规模预计将从 2024 年的1,312 亿美元增至 2029 年底的 1,893 亿美元，预测期内复合年增长率为 7.6%。

北美地区预计将从 2024 年的 589 亿美元成长到 2029年终的857 亿美元，复合年增长率为 7.8%。此外，欧洲地区预计将从2024年的341亿美元成长到2029年终的478亿美元，复合年增长率为7.0%。

该报告调查了全球血液疾病治疗和诊断市场，并提供了市场概况、市场影响因素和市场机会分析、新兴技术和技术发展趋势、市场规模趋势和预测以及各种细分，并总结了详细的区域主要企业分析、竞争格局和概况。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场概况

第二章 市场概况

• 概述
• PESTEL分析
• 波特五力分析
• 血液检测设备供应链与物流

第三章市场动态

• 市场驱动因素
• 市场限制因素
• 市场机会

第四章 药品专利情形及近期发展现状

• 专利情况
• 新核准

第五章新兴技术与发展

• 概述
• 新技术
• AI辅助诊断
• 次世代定序（NGS）
• 微流体和实验室晶片设备
• 基因治疗
• 免疫疗法
• 临床试验

第六章市场区隔分析

• 细分细分
• 按市场分类
• 血液疾病诊断市场
• 血液疾病诊断市场：依产品类型
• 血液疾病诊断市场：依最终用户分类
• 血液学药物市场
• 血液学药物市场：依药物类型
• 地域分布
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第七章 竞争讯息

• 主要企业
• 血液疾病诊断剂
• 治疗血液疾病的药物
• 罕见血液疾病药物新开发商

第8章附录

• 调查方法
• 来源
• 简称
• 公司简介
• ABBOTT
• AMGEN INC.
• BIO-RAD LABORATORIES INC.
• BRISTOL MYERS SQUIBB CO.
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• NOVARTIS AG
• SANOFI
• SYSMEX CORP.
• TAKEDA PHARMACEUTICAL CO. LTD.

The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.

The North American market for drugs and diagnostics for hematological disorders is expected to grow from $58.9 billion in 2024 and is projected to reach $85.7 billion by the end of 2029, at a CAGR of 7.8% during the forecast period of 2024 to 2029.

The European market for drugs and diagnostics for hematological disorders is expected to grow from $34.1 billion in 2024 and is projected to reach $47.8 billion by the end of 2029, at a CAGR of 7.0% during the forecast period of 2024 to 2029.

Report Scope

This report covers the worldwide market for the drugs used to treat hematological disorders, as well as the devices and reagents used to diagnose these diseases. Based on product type, the diagnostic market for hematological disorders is divided into reagents & instruments and software. By end user, the market is segmented into hospitals, diagnostic labs, and others. On the basis of drug type, the drugs used to treat hematological disorders are divided into oncology drugs and non-oncology drugs.

The market is divided into four geographic regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. The report also covers approved drugs, the pipeline analysis, innovative research, opportunities within the market, and profiles of leading companies.

The growing number of individuals with leukemia is the main reason for the market's growth and the development of more effective drugs.

Report Includes

• 49 data tables and 44 additional tables
• An overview of the current and future global markets for drugs and diagnostics for hematological disorders
• Analyses of the global market trends, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2029, and projected CAGRs through 2029
• Estimate of the current market size and revenue growth prospects, along with a market share analysis by segment, product, end user, drug type, and region
• Facts and figures pertaining to the market dynamics, current and emerging technologies, regulations, cancer incidence, and the impact of various macroeconomic factors
• A look at treatment strategies, such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, as well as testing and screening methods for diagnosis
• Review of technological developments, product introductions, and other recent industry activity of the major players
• Discussion of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices
• An analysis of recent patents
• A look at the competitive landscape, including companies' market shares, M&A activity and venture funding
• Profiles of the leading market players, including Danaher, Abbott, Sysmex Corp., Bristol Myers Squibb Co., and F. Hoffmann-La Roche Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• PESTEL Analysis
• Political
• Economic
• Social
• Technological
• Environmental
• Legal
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential of New Entrants
• Threat of Substitutes
• Competition in the Industry
• Supply Chain and Logistics for Hematological Instruments

Chapter 3 Market Dynamics

• Market Drivers
• Incidence of Blood Disorders
• Rising Use of Automation
• Diagnosis of Hematology Disorders
• Increasing Government and Private Funding for Treatment
• Market Restraints
• High Cost of Instruments
• High Cost of Treatment
• Reimbursement Challenges for Physicians
• Market Opportunities
• Rising Health Awareness
• Emerging Economies

Chapter 4 Patent Landscape and Current Developments in Drugs

• Patent Landscape
• New Approvals

Chapter 5 Emerging Technologies and Developments

• Overview
• Emerging Technologies
• AI-Assisted Diagnosis
• Next-Generation Sequencing (NGS)
• Microfluidics and Lab-on-a-Chip Devices
• Gene Therapies
• Immunotherapies
• Clinical Trials

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Segmentation by Market
• Hematological Disorders Diagnostics Market
• Hematological Disorders Diagnostic Market, By Product Type
• Hematological Disorders Diagnostic Market, By End User
• Hematology Drug Market
• Hematology Drug Market, By Drug Type
• Geographic Breakdown
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Leading Companies
• Hematological Disorder Diagnostics
• Hematological Disorder Drugs
• New Developers of Drugs for Rare Hematology Disorders

Chapter 8 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBOTT
• AMGEN INC.
• BIO-RAD LABORATORIES INC.
• BRISTOL MYERS SQUIBB CO.
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• NOVARTIS AG
• SANOFI
• SYSMEX CORP.
• TAKEDA PHARMACEUTICAL CO. LTD.

List of Tables

• Summary Table : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
• Table 1 : Blood-Related Disorders
• Table 2 : Incidence of Blood Cancer Types in U.S., 2023
• Table 3 : Total Cost of Care for CLL Patients Treated in the U.S., 2023
• Table 4 : Hematology Drugs and their Patent Expiration Dates, 2024
• Table 5 : Approved Hematology Drugs, 2023
• Table 6 : Clinical Trial Studies on Leukemia, March 2024
• Table 7 : Clinical Trial Studies on Lymphoma, March 2024
• Table 8 : Clinical Trial Studies on Bleeding Disorders, March 2024
• Table 9 : Clinical Trial Studies on Myelofibrosis, March 2024
• Table 10 : Clinical Trial Studies on Anemia, March 2024
• Table 11 : Clinical Trial Studies on Multiple Myeloma, March 2024
• Table 12 : Clinical Trial Studies on Thalassemia, March 2024
• Table 13 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 14 : Global Market for Diagnostics for Hematological Disorders, by Region, Through 2029
• Table 15 : Global Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 16 : Global Market for Hematology Instruments and Software, by Region, Through 2029
• Table 17 : Global Market for Hematology Reagents, by Region, Through 2029
• Table 18 : Global Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 19 : Global Market for Hematology Diagnosis in Diagnostic Centers, by Region, Through 2029
• Table 20 : Global Market for Hematology Diagnosis in Hospitals and Clinics, by Region, Through 2029
• Table 21 : Global Market for Hematology Diagnosis in Other End Users, by Region, Through 2029
• Table 22 : Global Market for Hematology Drugs, by Region, Through 2029
• Table 23 : Global Market for Hematology Drugs, by Drug Type, Through 2029
• Table 24 : Drugs Approved for Hematologic Cancers
• Table 25 : Global Market for Hematology Oncology Drugs, by Region, Through 2029
• Table 26 : Global Market for Hematology Non-Oncology Drugs, by Region, Through 2029
• Table 27 : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, Through 2029
• Table 28 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
• Table 29 : North American Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 30 : North American Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 31 : North American Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 32 : North American Market for Hematology Drugs, by Drug Type, Through 2029
• Table 33 : European Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
• Table 34 : European Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 35 : European Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 36 : European Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 37 : European Market for Hematology Drugs, by Drug Type, Through 2029
• Table 38 : Incidence of Blood-Related Cancers, by Country, 2022
• Table 39 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Country, Through 2029
• Table 40 : Asia-Pacific Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 41 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 42 : Asia-Pacific Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 43 : Asia-Pacific Market for Hematology Drugs, by Drug Type, Through 2029
• Table 44 : Asia-Pacific Incidence of Blood-Related Cancers, by Country, 2022
• Table 45 : RoW Market for Drugs and Diagnostics for Hematological Disorders, by Segment, Through 2029
• Table 46 : RoW Market for Diagnostics for Hematological Disorders, by Product Type, Through 2029
• Table 47 : RoW Market for Diagnostics for Hematological Disorders, by End User, Through 2029
• Table 48 : RoW Market for Hematology Drugs, by Drug Type, Through 2029
• Table 49 : Revenue Generated by Drugs for Hematology Disorders, 2023
• Table 50 : New Developers of Drugs for Hematology Disorders
• Table 51 : Report Sources
• Table 52 : Abbreviations Used in This Report
• Table 53 : Abbott: Company Snapshot
• Table 54 : Abbott: Financial Performance, F.Y. 2022 and 2023
• Table 55 : Abbott: Product Portfolio
• Table 56 : Abbott: News/Key Developments, 2023
• Table 57 : Amgen Inc.: Company Snapshot
• Table 58 : Amgen Inc.: Financial Performance, FY 2022 and 2023
• Table 59 : Amgen Inc.: Product Portfolio
• Table 60 : Amgen Inc.: News/Key Developments, 2021-2024
• Table 61 : Bio-Rad Laboratories Inc.: Company Snapshot
• Table 62 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
• Table 63 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 64 : Bio-Rad Laboratories Inc.: News/Key Developments, 2023
• Table 65 : Bristol Myers Squibb Co.: Company Snapshot
• Table 66 : Bristol Myers Squibb Co.: Financial Performance, FY 2022 and 2023
• Table 67 : Bristol Myers Squibb Co.: Product Portfolio
• Table 68 : Bristol Myers Squibb Co.: News/Key Developments, 2023 and 2024
• Table 69 : Danaher Corp.: Company Snapshot
• Table 70 : Danaher Corp.: Financial Performance, FY 2022 and 2023
• Table 71 : Danaher Corp.: Product Portfolio
• Table 72 : Danaher Corp.: News/Key Developments, 2022-2024
• Table 73 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 74 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
• Table 75 : F. Hoffmann-La Roche Ltd: Product Portfolio
• Table 76 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
• Table 77 : Novartis AG: Company Snapshot
• Table 78 : Novartis AG: Financial Performance, FY 2022 and 2023
• Table 79 : Novartis AG: Product Portfolio
• Table 80 : Novartis AG: News/Key Developments, 2022
• Table 81 : Sanofi: Company Snapshot
• Table 82 : Sanofi: Financial Performance, FY 2022 and 2023
• Table 83 : Sanofi: Product Portfolio
• Table 84 : Sanofi: News/Key Developments, 2023
• Table 85 : Sysmex Corp.: Company Snapshot
• Table 86 : Sysmex Corp.: Financial Performance, FY 2022 and 2023
• Table 87 : Sysmex Corp.: Product Portfolio
• Table 88 : Sysmex Corp.: News/Key Developments, 2021-2023
• Table 89 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
• Table 90 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2021 and 2022
• Table 91 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
• Table 92 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023

List of Figures

• Summary Figure : Global Market for Drugs and Diagnostics for Hematological Disorders, by Region, 2021-2029
• Figure 1 : Market Dynamics of Drugs and Diagnostics for Hematological Disorders
• Figure 2 : Incidence of Blood Cancer Types, by Region, 2022
• Figure 3 : Clinical Trial Phases of Drugs for Various Blood-Related Disorders, March 2024
• Figure 4 : Global Market Shares of Drugs and Diagnostics for Hematological Disorders, by Segment, 2023
• Figure 5 : Global Market Shares of Diagnostics for Hematological Disorders, by Product Type, 2023
• Figure 6 : Global Market Shares of Diagnostics for Hematological Disorders, by End User, 2023
• Figure 7 : Global Market Shares of Hematology Drugs, by Drug Type, 2023
• Figure 8 : North American Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
• Figure 9 : New Cases of Leukemia, Lymphoma and Myeloma in U.S., 2023
• Figure 10 : European Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
• Figure 11 : Asia-Pacific Market Shares of Drugs and Diagnostics for Hematological Disorders, by Country, 2023
• Figure 12 : Abbott: Revenue Shares, by Business Unit, F.Y. 2023
• Figure 13 : Abbott: Revenue Shares, by Country/Region, FY 2023
• Figure 14 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 15 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 16 : Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 17 : Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 18 : Bristol Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
• Figure 19 : Bristol Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
• Figure 20 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2023
• Figure 21 : Danaher Corp.: Revenue Shares, by Country/Region, FY 2023
• Figure 22 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
• Figure 23 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
• Figure 24 : Novartis AG: Revenue Shares, by Business Unit, FY 2023
• Figure 25 : Novartis AG: Revenue Shares, by Country/Region, FY 2023
• Figure 26 : Sanofi: Revenue Shares, by Business Unit, FY 2023
• Figure 27 : Sanofi: Revenue Shares, by Country/Region, FY 2023
• Figure 28 : Sysmex Corp.: Revenue Shares, by Business Unit, FY 2023
• Figure 29 : Sysmex Corp.: Revenue Shares, by Country/Region, FY 2023
• Figure 30 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2022